April 29, 2016   Management Q&A   Christopher  Schaber Soligenix Fosters Potent Pipeline of Orphan Disease Compounds in Areas of Unmet Medical Need     With a robust pipeline of drugs in late-stage clinical trials and milestones on the horizon, it's no wonder Soligenix Inc.'s CEO, Dr. Christopher Schaber, holds an optimistic view of the company's future. (4/27/16)   Share this interview:       Bob Moriarty What Steve Jobs Knew About the Internet Can Make You a Better Gold Investor   Of all the people in the tech world, Steve Jobs perhaps understood the potential of the Internet better than any of his peers. Bob Moriarty of 321Gold discusses how Jobs' insight can provide lessons on gold manipulation and what moves markets. (4/27/16)   Share this interview:       Jack Chan Are We or Are We Not in a New Gold Bull Market?   Technical analyst Jack Chan has examined the charts and says that if we are in a new bull market, prices in both gold and gold equities should begin to pull back and consolidate soon. (4/26/16)   Share this interview:       Michael Ballanger The Significance of Rising Commodities Prices…   Precious metals expert Michael Ballanger expounds on how Federal Reserve policy affects the commodities markets, and expresses cautious optimism about how that policy will play out in gold. (4/27/16)   Share this interview:     Barry Allan Ryan  Hanley LiTHIUM X Is Not Alone—Profiling This Marketplace Darling and Others in the Sweet Spot   After several years of bear markets for miners, many mining equities have lept upward in the last few months. LiTHIUM X Energy ranks among the leaders of the pack. Barry Allan and Ryan Hanley of Mackie Research put out a report in March for the PDAC convention, highlighting a number of promising mining companies. In this interview they profile a handful of those companies, including LiTHIUM X. (4/25/16)     "RD is one of the first major projects that has been able to actually get through the permitting phase in Colombia. . ." View More   "The economics of RPM's Lincoln Hill project hold up in today's gold price environment. . ." View More     Share this interview:       Joseph  Pantginis Let Volatility Power Your Micro-Cap Biotechs   ROTH Capital Partners' Joseph Pantginis falls into that old-fashioned category of analysts who believe that good data can't help but drive a stock—no matter how far into the depths it may have sunk—and presents his detailed growth theory on two names, plus two picks for investors to do further diligence on. (4/27/16)     "The interim data from the Phase 1a/1b studies of Supinoxin and RX-3117 will really increase the visibility for RNN this year. . ." View More     Share this interview:       Adrian Day Hold Reservoir Minerals After Takeout: Adrian Day   Adrian Day shares his initial thoughts on the Reservoir Minerals/Nevsun deal. (4/24/16)   Share this interview:     Click Here to update your preferences. Or to unsubscribe, please click here.